Recent proof-backed calls
Public preview of tracked recommendations linked to source content, observed prices, and outcomes.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
Short listing for a YouTube interview filmed at the 2026 Abundance360 Summit with Ben Lamm (Colossal) titled “AI + Synthetic Biology: The Most Transformative Technology in Human History.” The listing notes the video but the transcript could not be retrieved. Content likely promotes Colossal’s synthetic biology/de‑extinction work and argues AI+synthbio is transformational. No new corporate filings, financing, or measurable operational updates are present in the item.
Latest market-close explanation
**CRSP** (CRISPR Therapeutics AG) moved **+7.05%** on 2026-04-13, closing at **$54.83** after a previous close of **$51.22**. Intraday range was **$51.05** to **$55.09**. Volume changed **+110.9%** versus the prior session. Recent internal coverage also touched CRSP: **Big Ideas 2026: Multiomics**.
Current stance
Top authors on this ticker
Active and historical plays
Unlock full ticker monitoring
Create an account to access full ticker history, alerts, Telegram workflows, and trust-weighted live rankings across authors, plays, and market events.